Enhancement of hepatitis A propagation in tissue culture with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
The adenosine analog 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) was found to increase the production of hepatitis A (HAV) antigen in two monkey kidney cell lines (Frhk-4 and Vero cells). DRB, a known inhibitor of the synthesis of messenger RNA, caused moderate changes in cell morphology. However, Frhk-4 cells could be maintained for several weeks at 80 microM of DRB, the concentration that caused maximal enhancement on HAV. DRB should be present from about the time of virus inoculation and its strongest effect was seen at low multiplicities of infection. Using radioimmunofocus assay it could be shown that DRB increased the amount of infectious virus. DRB treatment was applied in primary isolation of HAV from feces. In nine of ten strains HAV antigen expression was strongly increased and in six of the ten strains infectivity of harvested material increased by one 10log or more. DRB thus seems to be a useful enhancer of HAV growth in tissue culture.
Widell
A
A
Department of Medical Microbiology, University of Lund, Malmö General Hospital, Sweden.
Hansson
B G
BG
Nordenfelt
E
E
Oberg
B
B
D000818:Animals; D000956:Antigens, Viral / Q000302:isolation & purification; D002460:Cell Line; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology*; D035921:Hepatitis A Antigens; D006507:Hepatovirus / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D012263:Ribonucleosides / Q000494:pharmacology*; D014776:Virus Cultivation / Q000379:methods*
D000956:Antigens, Viral; D035921:Hepatitis A Antigens; D012263:Ribonucleosides; D004004:Dichlororibofuranosylbenzimidazole